Disease relevance of GADOPENTETATE DIMEGLUMINE

• Imaging of myocardial infarction: comparison of magnevist and gadophrin-3 in rabbits [1].
• Resovist was administered intravenously at doses of 4, 8, and 16 mumol of iron per kilogram of body weight [2].
• An in vitro internalization study showed that Av-G6Gd accumulated and was internalized into SHIN3 cells (a human ovarian cancer) 50- and 3.5-fold greater than Gd-DTPA (Magnevist) and G6-(1B4M-Gd)(256) (G6Gd) [3].
• CONCLUSIONS: The dose-dependency and rate of decay of efficacy of Resovist in cirrhosis were similar to those in normal liver, although the efficacy was less in cirrhotic liver and both the dose-dependency and rate of decay of efficacy were dependent on imaging parameters [4].
• Gadopentetate-dimeglumine-enhanced MR imaging of gliomatosis cerebri: appearance mimicking leptomeningeal tumor dissemination [5].

High impact information on GADOPENTETATE DIMEGLUMINE

• MATERIALS AND METHODS: Thirty-six patients with liver lesions received a bolus injection of Resovist (SH U 555 A; Schering, Berlin, Germany) at a dose of 4, 8, or 16 micromol iron per kilogram body weight (micromol Fe/kg) [6].
• The latter were preferred by the colon carcinoma cell line used here and taken up much faster (12 h) than the smaller carboxydextran-coated Resovist (48 h) [7].
• A multicompartment pharmacokinetic model was proposed to quantitatively describe the distribution of the contrast agent gadopentetate-dimeglumine (Gd) in an experimental spinal cord injury (SCI) [8].
• The results indicate: 1) lack of uptake of Gd in normal cord tissue, 2) rapid exchange of Gd between plasma and cerebrospinal fluid in both normal and injured cord tissues, and 3) slower uptake of Gd in injured cord [8].
• The exponential clearance rate constant, (kappa), and filtration fraction (FF) have been measured for dialysis of Gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) (Magnevist, Berlex, Wayne, NJ) solutions by using a Look-Locker imaging technique under conditions of flow [9].

Chemical compound and disease context of GADOPENTETATE DIMEGLUMINE

• OBJECTIVES: This study aimed to determine the changes during ischemia in the myocardial first-pass kinetics of DTPA, an extracellular tracer that is currently used for assessing myocardial perfusion with magnetic resonance imaging (Magnevist) [10].
• We report a case of chronic progressive myelopathy with an unusual long-standing gadolinium-diethylenetriamine pentaacetic acid (Magnevist, Berlex Laboratories) enhanced spinal cord lesion demonstrated on MRI, through a 14 month follow-up period [11].

Biological context of GADOPENTETATE DIMEGLUMINE

• Application of a superparamagnetic iron oxide (Resovist) for MR imaging of human cerebral blood volume [12].
• Using a 1.5-T Gyroscan ACS II-imager (Philips, Hamburg, Germany) and a double breast coil with the patient lying in a prone position, 0.1 mmol/kgbw Magnevist (Schering, Berlin, Germany) were injected into the cubital vein to obtain dynamic axial and coronal T1-weighted fast-field-echo images every minute up to 7 min after bolus injection [13].

Anatomical context of GADOPENTETATE DIMEGLUMINE

• MRI revealed clear signal changes attributable to Resovist-containing microglia in the mouse brain [14].
• RATIONALE AND OBJECTIVES: The objective of the two pivotal phase 3 studies was to evaluate the safety and efficacy of OptiMARK (Gd-DTPA-bis(methoxyethylamide) [Gd-DTPA-BMEA]) compared with Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system [15].
• We retrospectively reviewed 330 T1-weighted sagittal images, 80 T2-weighted sagittal images, and 83 gadopentetate-dimeglumine-enhanced scans of normal adults to determine the MR appearance of the normal adult clivus [16].
• Eleven patients with known or suspected optic nerve lesions and eight normal subjects were examined with spin-echo technique at 1.5 T with unenhanced T1-weighted imaging, IV gadopentetate-dimeglumine-enhanced T1-weighted imaging, and enhanced T1-weighted imaging with fat suppression [17].
• After positioning a catheter in the hepatic artery, we performed 3D inversion recovery GRE MRI after IA and IV gadopentetate-dimeglumine contrast injections at doses of 0.04 and 0.1 mmol/kg, respectively [18].

Associations of GADOPENTETATE DIMEGLUMINE with other chemical compounds

• In crossover studies, 23 of 287 (8%) subjects receiving MultiHance experienced AE compared with 25 of 295 (9%) receiving gadopentetate dimeglumine (Magnevist) [19].
• RATIONALE AND OBJECTIVES: The authors assess the efficacy of static and dynamic magnetic resonance (MR) imaging using the superparamagnetic iron oxide SHU-555A (Resovist) versus standard dose of gadolinium (Gd)-DTPA in patients with focal liver lesions [20].
• A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial [21].
• Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla [22].
• The introduction of a lipophilic moiety into the gadolinium chelate Gd-DTPA (dimeglumine gadopentetate, Magnevist) yielded Gd-EOB-DTPA (short form), which has potential as a magnetic resonance contrast agent for liver mass screening [23].

Gene context of GADOPENTETATE DIMEGLUMINE

• Resovist for imaging of hepatocellular carcinoma in the cirrhotic liver [24].
• Seventeen patients with malignant focal liver lesions (liver metastases, n=7), hepatocellular carcinomas (HCC, n=9), and cholangiocellular carcinoma (CCC, n=1) underwent presurgical Resovist-enhanced MRI and CTAP [25].
• Large iron oxide particles are used for bowel contrast [AMI-121 (i.e. Lumirem and Gastromark) and OMP (i.e. Abdoscan), mean diameter no less than 300 nm] and liver/spleen imaging [AMI-25 (i.e. Endorem and Feridex IV, diameter 80-150 nm); SHU 555A (i.e. Resovist, mean diameter 60 nm)] [26].
• We then administered microglia, which were labeled with enhanced green fluorescent protein (EGFP) gene and Resovist, into the carotid artery [27].
• MRI revealed clear signal changes attributable to Resovist-containing microglia in Abeta-injected areas [27].

Analytical, diagnostic and therapeutic context of GADOPENTETATE DIMEGLUMINE

• The results from this study indicate that DSC perfusion imaging using Resovist can be used to assess the efficacy of CNS-active drugs and may play a role in the development of novel psychiatric therapies at the preclinical level [28].
• Dedicated clinical trials are warranted to assess the potentials of Resovist for perfusion MRI and fMRI [12].
• MRA of the portal venous system was performed on 48 patients before and after intravenous injection of a new SPIO (Resovist, Schering AG, Berlin, Germany) [29].
• Gd-DTPA (Magnevist, Berlex, Wayne, NJ) extraction fractions (EF) have been measured for three dialysis filter types using an echo-planar imaging (EPI) Look-Locker T1 measurement technique under conditions of fast and slow flow [30].
• Measurement of relative cerebral blood volume changes with visual stimulation by 'double-dose' gadopentetate-dimeglumine-enhanced dynamic magnetic resonance imaging [31].

References